US Drugmakers and Politicians Clash Over Abortion Pill Ruling

More than 300 executives from biotech and pharmaceutical companies, including Pfizer and Biogen, signed an open letter calling for the reversal of a federal judge's decision to suspend sales of the abortion pill mifepristone. The ruling could undermine the FDA's authority to regulate drugs, severely weaken the agency, and hinder access to new treatments. The Department of Justice has appealed the decision, and the letter warns that the decision puts the entire industry at risk and sets a precedent for undermining the agency's authority to approve drugs, adding regulatory uncertainty that they warned would disincentivize investment in new treatments.